NCI Offers Two Cancer Biomarkers for License | GenomeWeb
NEW YORK (GenomeWeb News) – The National Cancer Institute is making two newly developed cancer biomarker technologies available for licensing, one for early diagnosis of ovarian cancer and one to predict patient response to chemotherapy.
The NCI’s Cell and Cancer Biology branch today issued details about the technology that addresses ovarian cancer, which it said is the fifth most common cancer in US women, and which killed more than 15,000 women in the US in 2006, making it three times more deadly than breast cancer.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The Wall Street Journal speaks with patients affected by questionable test results from Theranos.

Researchers link variants in TACR3 to hot flashes during menopause, Live Science reports.

Kuwait says it will alter its law requiring citizens and visitors to provide DNA samples, New Scientist reports.

In Science this week: convergent evolution in bird hemoglobin, and more.